AMRA Medical at AASLD 2022: Superior MRI Technology and Informatics for the Full Continuum of Liver Disease

LINKÖPING, Sweden–(BUSINESS WIRE)–AMRA Medical and its collaborators will present seven abstracts across the entire continuum of chronic liver disease disease progression, with studies including individuals with early liver disease (nonalcoholic fatty liver disease; NAFLD) through cirrhosis to liver transplantation. The data presented suggest that it is possible to use the same objective, accurate and precise magnetic resonance (MR)-based technology and informatics-based image analysis to assess both physical frailty and sarcopenia during the course of the disease. Those attending AASLD The Liver Meeting in November can learn more about how AMRA technology and informatics are used in these studies and how it all underpins our clinical applications, the AMRA® MAsS scan and the AMRA® BCP scan , by attending the abstract presentations or visiting the exhibit at AMRA booth #731.

AMRA’s magnetic resonance imaging (MRI)-based technology accurately measures various characteristics, such as muscle fat infiltration, muscle volume and fat distribution, and objectively assesses muscle quality and quantity. The imaging-based technology and unique information platform can provide insight into different muscle phenotypes at different states of disease progression, attracting many internal and external research groups – from those investigating the biological nuances of liver disease to those developing the next generation liver disease therapeutics and interventions. Such research has led to the AMRA clinical proposal, which can assist clinicians in making care decisions for liver patients.

Two abstracts will be presented, including individuals with early liver disease and the potential for risk stratification based on muscle composition. They include:

“Muscle composition but not liver fat predicts all-cause mortality in UK Biobank imaging study”

“Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD”

Three abstracts—liver cirrhosis and two separate cohorts of liver transplant candidates—involving MR-based tests to assess frailty and sarcopenia will be presented. They include:

“​Imaging-Based Testing for Physical Frailty and Sarcopenia – Interim Results from the ACCESS-ESLD Cirrhosis Prospective Cohort Study​”

“Imaging-based test for sarcopenia – Interim results of a natural history study of the liver transplant waiting list”

“Severity of myosteatosis correlates with frailty in patients with end-stage liver disease”

Two abstracts will be presented demonstrating the utility of AMRA MR-based measurements of muscle and fat in liver transplant recipients. They include:

“Randomized controlled trial of low-calorie versus low-carbohydrate diet on metabophenotype in obese liver transplant patients”

“Relation between Metabophenotype and Atherogenic Lipoproteins in Liver Transplant Patients”

Looking at all seven abstracts together—which spans diverse cohorts in Europe and the US, from early chronic disease to post-liver transplant—suggests that AMRA’s technology is positioned to improve the way researchers and clinicians stratify patients based on risk, assess different stages of the disease and evaluate the effect of liver transplantation on health outcomes or the effect of other post-transplant interventions.

Eric Converse, CEO of AMRA Medical, commented: “We are so proud to see our years of research continue to help researchers develop more solutions for metabolic disorders such as liver disease. As part of our ambition to provide better healthcare for all, AMRA is excited to see our recently FDA-cleared AMRA® MAsS Scan be used to support clinical care decisions for patients with cirrhosis and those undergoing liver transplantation. It is empowering to see how this technology, as well as our FDA-cleared AMRA® BCP scan, which can assist clinicians in disease prevention by providing actionable patient insights, is making a real-world impact. We hope our technology and services reduce the burden on healthcare providers, allowing patients to stay healthier longer.”

Converse continued, “I hope attendees can see our abstracts, attend Dr. Mohammad Siddiqui’s plenary session, and then visit our booth to see how all this research has led to our amazing applications to support clinical solutions for surgery such as liver transplantation, chronic care such as cirrhosis and disease prevention.”

Visit the abstract presentations or visit our booth #731 to learn more about the utility of AMRA technology in liver disease research and in the clinic.

To contact us or read more about our clinical services Visit our website and to find information about abstracts, read more here.

Leave a Comment